PortfoliosLab logo
Franklin Genomic Advancements ETF (HELX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

ETF Info

ISIN

US35473P5200

CUSIP

35473P520

Inception Date

Feb 25, 2020

Region

Developed Markets (Broad)

Leveraged

1x

Index Tracked

No Index (Active)

Asset Class

Equity

Asset Class Size

Multi-Cap

Asset Class Style

Growth

Expense Ratio

HELX has an expense ratio of 0.50%, placing it in the medium range.


Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Franklin Genomic Advancements ETF (HELX) returned -9.23% year-to-date (YTD) and -17.62% over the past 12 months.


HELX

YTD

-9.23%

1M

2.05%

6M

-8.28%

1Y

-17.62%

5Y*

-2.00%

10Y*

N/A

^GSPC (Benchmark)

YTD

1.30%

1M

12.94%

6M

1.49%

1Y

12.48%

5Y*

15.82%

10Y*

10.87%

*Annualized

Monthly Returns

The table below presents the monthly returns of HELX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20256.39%-4.66%-7.73%0.89%-3.88%-9.23%
2024-2.26%7.99%1.86%-8.22%3.24%2.07%6.17%-1.06%-2.61%-6.77%2.62%-6.97%-5.32%
20235.36%-6.27%2.12%-1.77%-1.09%2.42%3.31%-1.45%-7.95%-10.04%9.31%9.36%1.14%
2022-19.37%-3.80%-1.88%-11.81%2.46%-3.95%10.57%-9.41%-7.59%4.30%3.31%-5.72%-37.89%
20218.19%-6.00%-3.73%6.47%-5.43%18.63%2.50%5.69%-6.74%1.73%-6.03%-2.78%9.80%
2020-6.65%18.17%12.23%3.63%11.13%3.89%-1.07%1.22%12.97%10.43%85.05%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of HELX is 2, meaning it’s performing worse than 98% of other ETFs on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of HELX is 22
Overall Rank
The Sharpe Ratio Rank of HELX is 22
Sharpe Ratio Rank
The Sortino Ratio Rank of HELX is 22
Sortino Ratio Rank
The Omega Ratio Rank of HELX is 22
Omega Ratio Rank
The Calmar Ratio Rank of HELX is 55
Calmar Ratio Rank
The Martin Ratio Rank of HELX is 11
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Franklin Genomic Advancements ETF (HELX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Franklin Genomic Advancements ETF Sharpe ratios as of May 17, 2025 (values are recalculated daily):

  • 1-Year: -0.74
  • 5-Year: -0.08
  • All Time: 0.06

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Franklin Genomic Advancements ETF compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History

Franklin Genomic Advancements ETF provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.


0.00%0.05%0.10%0.15%0.20%$0.00$0.02$0.04$0.06$0.08$0.10$0.1220202021202220232024
Dividends
Dividend Yield
PeriodTTM20242023202220212020
Dividend$0.00$0.00$0.00$0.00$0.12$0.05

Dividend yield

0.00%0.00%0.00%0.00%0.24%0.12%

Monthly Dividends

The table displays the monthly dividend distributions for Franklin Genomic Advancements ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025$0.00$0.00$0.00$0.00$0.00$0.00
2024$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2023$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2022$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2021$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.12$0.12
2020$0.05$0.05

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Franklin Genomic Advancements ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Franklin Genomic Advancements ETF was 58.75%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Franklin Genomic Advancements ETF drawdown is 54.92%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-58.75%Sep 8, 2021900Apr 8, 2025
-27.15%Mar 5, 20208Mar 16, 202025Apr 24, 202033
-26.01%Feb 16, 202115Mar 8, 2021101Jul 30, 2021116
-8.87%Sep 3, 20203Sep 8, 202019Oct 5, 202022
-8.02%Oct 14, 202014Nov 2, 20203Nov 5, 202017

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...